相关实验视频
Updated: Jan 16, 2026

12:43
On-Chip Endothelial Inflammatory Phenotyping
Published on: July 21, 2012
11.4K
巴巴酸通过调节HIF1A/FLT1通路来抑制高血压中的炎症反应和内皮功能障碍:计算机辅助的生物标记研究和实验验证
Xu-Zhao Li1, Zhen-Tao Lv1, Xiang Yu1
1College of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guian new area, 550025, PR China.
Computers in biology and medicine
|September 30, 2025
概括
巴巴巴酸通过减少炎症和内皮功能障碍,显示出治疗高血压的潜力. 这项研究证实了其在高血压模型中降低血压和改善器官损伤方面的有效性.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 生物信息学是一种生物信息学.
背景情况:
- 高血压是全球主要的健康风险,导致心血管和脑血管死亡率.
- 巴巴酸具有潜在的抗高血压特性,但其机制需要进一步阐明.
- 了解酸的作用对于开发新型高血压疗法至关重要.
研究的目的:
- 研究巴巴酸在高血压治疗中的治疗潜力.
- 阐明巴巴酸抗高血压作用的潜在机制.
- 用细胞和动物模型验证发现.
主要方法:
- 生物标签主导的研究模型的生物信息学分析.
- 建立细胞 (Ang II) 和动物 (L-NAME) 的高血压模型.
- 在体外 (HUVEC扩散) 和体内 (血压,组织病理) 实验.
主要成果:
- 生物信息学确定了十个关键的生物标签,其中HIF1A和FLT1是参与炎症和内皮功能障碍的主要目标.
- 巴巴酸增强了HUVEC的扩散,并在体外调节了10个生物标签和下游目标.
- 在高血压小鼠中,巴巴丁酸降低了血压,改善了组织损伤,并抑制了HIF1A/FLT1水平.
结论:
- 巴巴基酸通过向HIF1A/FLT1通路有效治疗高血压.
- 该化合物抑制炎症反应,并改善高血压中的内皮功能障碍.
- 这些发现验证了生物标签研究模式,并支持巴巴酸作为治疗剂.
相关概念视频
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.3K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K
Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.5K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.5K
Antihypertensive Drugs: Direct Renin Inhibitors
1.3K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
936
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
936
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
441
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
441
Atherosclerosis III: Management
321
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
321

